Establishing norms in an oncological service setting and of medico-technological standards for delivering oncological care to the population of Ukraine presupposes a uniform notion-terminological apparatus to be devised. The article presents current interpretation of the meaning of most widely used, leading traditional and newly coined terms and notions common in practical oncology, that subdivision of its dealing with prophylaxis and diagnosis of malignant tumors, for broad sections of medical workers who were not specially trained in the field.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Jun, an Oncological Foe or Friend?
Int J Mol Sci
January 2025
Vascular Biology and Translational Research, Department of Pathology, School of Biomedical Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia.
Jun/JUN is a basic leucine zipper (bZIP) protein and a prototypic member of the activator protein-1 (AP-1) family of transcription factors that can act as homo- or heterodimers, interact with DNA elements and co-factors, and regulate gene transcription. Jun is expressed by both immune and inflammatory cells. Jun is traditionally seen as an oncoprotein that regulates processes involved in transformation and oncogenesis in human tumours.
View Article and Find Full Text PDFNavigating Emergency Management of Cancer Patients: A Retrospective Study on First-Time, End-Stage, and Other Established Diagnoses in a High Turnover Emergency County Hospital.
Medicina (Kaunas)
January 2025
Department of Surgery II, Emergency Medicine, University of Medicine and Pharmacy "Grigore. T. Popa", 700115 Iasi, Romania.
: The incidence and prevalence of cancers are increasing worldwide, with special emphasis placed on prevention, early detection, and the development of new therapeutic strategies that strongly impact patient outcomes. Limited data are available about emergency care's role in treating patients with cancer. This study aims to determine the burden of end-stage and first-time diagnosis of cancer on emergency care in a high-turnover emergency care center.
View Article and Find Full Text PDFCirculating, Extracellular Vesicle-Associated Tissue Factor in Cancer Patients with and without Venous Thromboembolism.
Biomolecules
January 2025
Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell'Area Critica, University of Pisa, 56126 Pisa, Italy.
Cancer is characterized by chronic inflammation and hypercoagulability, with an excess of venous thromboembolism (VTE). Tissue factor, the initiator of blood coagulation, circulates associated with extracellular vesicles (EV-TF). Studies investigating EV-TF between cancer-associated and non-cancer-associated VTE are lacking.
View Article and Find Full Text PDFPredictive Factors for the Discontinuation of Pressurized Intraperitoneal Aerosol Chemotherapy: Enhancing Patient Selection to Improve Oncological Outcomes-A Single-Center Experience.
Cancers (Basel)
January 2025
Surgical Unit of Peritoneum and Retroperitoneum Surgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
: Since 2011, Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) has emerged as a promising treatment option for patients with peritoneal surface malignancies (PSM) who are not eligible for cytoreductive surgery (CRS). Repeated minimal-invasive treatment is one of the key features and the current empirical standard treatment (ST) consists of at least three administrations over about three months. However, many patients are unable to complete the full course, limiting the potential benefits of PIPAC.
View Article and Find Full Text PDFValidity and Reliability of the Spanish Version of Godin-Shephard Leisure-Time Physical Activity Questionnaire in Prostate Cancer Patients.
Healthcare (Basel)
January 2025
Service de Pneumologie, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.
Background: Prostate cancer is highly prevalent in Spanish men. Although physical activity has benefits on several factors in prostate cancer survivors, this is diminished after medical oncology treatment. Cancer-related fatigue is one of the main barriers to physical activity, leading to a decrease in activity levels in these patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!